Kopran Limited (NSE:KOPRAN)

Market Cap	9.85B +14.6%
Revenue (ttm)	6.81B +8.2%
Net Income	257.31M -33.3%
EPS	5.33 -33.2%
Shares Out	n/a
PE Ratio	38.29
Forward PE	n/a
Dividend	3.00 (1.46%)
Ex-Dividend Date	Sep 4, 2025

Volume	140,820
Open	204.50
Previous Close	204.01
Day's Range	195.00 - 206.00
52-Week Range	107.00 - 219.00
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Kopran

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, s...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1958
• Employees: 1,024
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KOPRAN

Financial Performance

In fiscal year 2026, Kopran's revenue was 6.81 billion, an increase of 8.23% compared to the previous year's 6.30 billion. Earnings were 257.31 million, a decrease of -33.26%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 22, 2026

Data Sources Report a data error